Aligos Therapeutics Inc. (NASDAQ: ALGS)
$26.3450
-0.4050 ( +1.13% ) 116.2K
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Market Data
Open
$26.3450
Previous close
$26.7500
Volume
116.2K
Market cap
$94.11M
Day range
$25.9910 - $27.5150
52 week range
$6.7600 - $30.0000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Jun 28, 2024 |
| 8-k | 8K-related | 13 | May 31, 2024 |
| 8-k | 8K-related | 13 | May 22, 2024 |
| 8-k | 8K-related | 13 | May 15, 2024 |
| 10-q | Quarterly Reports | 69 | May 07, 2024 |
| 8-k | 8K-related | 15 | May 07, 2024 |
| ars | Annual reports | 1 | Apr 29, 2024 |
| def | Proxies and info statements | 3 | Apr 29, 2024 |
| pre | Proxies and info statements | 3 | Apr 16, 2024 |
| 8-k | 8K-related | 16 | Mar 12, 2024 |